Therapieresistenz bei schizophrenen Patienten - Aktueller stand

Translated title of the contribution: Therapy resistance in schipozophrenic - Aktueller stand

M. Lambert*, S. Moritz, S. Bender, C. Haasen, M. Krausz, D. Naber, Hamburg

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)


Therapy resistance in schizophrenic patients constitutes a severe clinical problem. Depending on the underlying definition prevalence ranges from 10 to 30 %. Until the end of the 80s, definitions of therapy resistance were closely associated with the persistence of positive symptoms. Since the middle of the 90s other outcome criteria have been additionally taken into consideration (e.g., negative symptoms and social functioning). The reasons for the failure of neuroleptic treatment are numerous: besides illness-related factors (e.g., negative symptomatology) patients' attitudes (e.g., reduced compliance) and treatment-related issues (e.g., neuroleptic side effects) play a prominent role. Regarding the treatment of these patients two factors are of major importance: (1) Early detection of therapy resistant patients and (2) an adequate psychopharmacotherapy. Prior to the introduction of further atypical neuroleptics, clozapine was considered the "gold standard" for treating these patients. The efficacy of new atypical antipsychotics like risperidone and olanzapine as well as other alternative treatment options (carbamazepine, lithium, benzodiazepines) is yet unclear.

Translated title of the contributionTherapy resistance in schipozophrenic - Aktueller stand
Original languageGerman
Pages (from-to)2-17
Number of pages16
Issue number1
Publication statusPublished - 2001
Externally publishedYes


  • Atypical antipsychotics
  • Pharmacotherapy
  • Refractory schizophrenia


Dive into the research topics of 'Therapy resistance in schipozophrenic - Aktueller stand'. Together they form a unique fingerprint.

Cite this